Immune Control gains $11.3M in venture capital

Immune Control of Conshohocken, Pennsylvania, has rounded up $11.3 million in venture capital from BioAdvance Ventures, a venture fund run by Quaker BioVentures, Domain Associates, NewSpring Capital and Anthem Capital. Immune Control says the money will fund two trials of serotonin antagonists as treatments for diseases marked by aberrant immune activation.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.